个人简介

Ph.D. in Microbiology and Immunology, University of Alabama, Birmingham, AL, 1998 Sang-Moo Kang, professor at Georgia State University, is focused on research to design and develop effective vaccines against viral diseases such as influenza virus and respiratory syncytial virus, to better understand vaccine-induced protective immune mechanisms, to study pathogen-induced inflammation and to develop anti-inflammatory therapeutics. The research is significant for the development of effective and universal flu vaccines and/or vaccination, creating a vaccine against RSV which does not currently exist and understanding neonatal immunology, vaccine-induced immunity and protective immune mechanisms and serious inflammatory pathogens, among other applications. Kang earned his Ph.D. in Microbiology and Immunology from University of Alabama.

研究领域

My research interests are to design and develop effective vaccines against viral diseases (Influenza virus, Respiratory Syncytial Virus), to better understand vaccine-induced protective immune mechanisms, and to study pathogen-induced inflammation, and to develop anti-inflammatory therapeutics.

Development of effective and universal flu vaccines and/or vaccination. Influenza is a serious human disease and there are challenging problems: Annual updates of vaccines and vaccination No protection against a new pandemic strain and bird flu Syringe-needle injection for delivery of vaccines involves pain and side effects as well as weak mucosal immunity. RSV (Respiratory syncytial virus): RSV is the leading cause of inflammatory bronchiolitis pneumonia, viral death in infants, and in some elderly adults. No vaccine against RSV is currently available. Millions of children and elderly are affected with RSV disease annually. Vaccine-induced immunity and protective immune mechanisms are not well understood. Better understanding of serious inflammatory pathogens: Influenza, RSV, co-infection with bacterial pneumonia. Neonatal immunology: Most vaccines are given to infants and young children. However, protective immune mechanisms in infants and young children remain largely unknown. Therefore, understanding protective immunity in infants and young children after vaccination is important and highly significant. Maternal immunization: To provide protective immunity in young infants until their immune system has fully matured. Development of Adjuvants: Development of safe and effective adjuvants is critically important for enhancing vaccine efficacy.

近期论文

查看导师最新文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Harvinder S. Gill, Sang-Moo Kang, Fu-Shi Quan, Richard W. Compans, Cutaneous immunization – an evolving paradigm in influenza vaccines. Expert Opinion on Drug Delivery (2014, In Press). Young-Tae Lee, Ki-Hye Kim, Eun-Ju Ko, Yu-Na Lee, Min-Chul Kim, Young-Man Kwon, Yinghua Tang, Min-Kyoung Cho, Youn-Jeong Lee, Sang-Moo Kang. New vaccines against influenza virus. Clinical and Experimental Vaccine Research. (2014, In Press). Min-Chul Kim, Jong-Seok Lee, Young-Man Kwon, Yu-Na Lee, Hye-Suk Hwang, Eun-Ju Ko, Jae-Min Song, Richard W. Compans, Sang-Moo Kang. Supplementation of Influenza Split Vaccines with a Conserved M2 Ectodomain Overcomes Strain-Specificity of Protection. Molecular Therapy (July, 2013 Under revision). Fu-Shi Quan, Eun-Ju Ko, Jae-Min Song, Richard W. Compans, Sang-Moo Kang. Mucosal adjuvants for influenza virus-like particle vaccine. Viral Immunology, 2014 (In Press). Min-Chul Kim, Jong-Seok Lee, Young-Man Kwon, Eunju O, Youn-Jeong Lee, Richard W Compans, Sang-Moo Kang. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antiviral Research, 2013 99(3): 328-335. Emily A. Hemann, Sang-Moo Kang, and Kevin L. Legge. Protective CD8 T cell mediated immunity against influenza A virus infection following influenza virus-like particle vaccination. J. Immunology, 2013, 191(5): 2486-2494. Fu-Shi Quan, Yeu-Chun Kim, Gye-Chang Jeon, Jae-Min Song, Richard W. Compans, Mark R. Prausnitz, Sang-Moo Kang. Long-term protective immunity from an influenza virus-like particle vaccine administered with a microneedle patch. Clinical and Vaccine Immunology, 2013. 20(9): 1433-1439. Min-Kyung Park, Young-Man Kwon, Vu NGO, Sieun Yoo, Young-Hee Cho, Sung-Moon Hong, Eun-Ju Ko, Hye Suk Hwang, Yu-Jin Jung, Dae-Won Moon, Eun-Ji Jeong, Min-Chul Kim, Ji-Hun Jang, Joon-Suk Oh, Cheol-Hyun Kim, Sang-Moo Kang. Lactobacillus plantarum DK119 from fermented food “Kimchi” confers protection against influenza virus by inducing a T helper type 1 immune response. PLOS ONE 2013. 8(10): e75368. Dong-Hun Lee, Sang-Woo Bae, Jae-Keun Park, Jung-Hoon Kwon, Seong-Su Yuk, Jae-Min Song, Sang-Moo Kang, Yong-Kuk Kwon, Hwi-Yool Kim, Chang-Seon Song. Virus-like particle vaccine protects against H3N2 canine influenza virus in dog. Vaccine, 2013, 31 (32): 3268-3273. Yeu-Chun Kim, Dae-Goon Yoo, Richard W. Compans, Sang-Moo Kang*, Mark R. Prausnitz. Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. Journal of Control Release. 2013, 172(2): 579-588. Marc Pearton, Daniela Pirri, Sang-MooKang, Richard W Compans, James C Birchall. Host responses in human skin after conventional intradermal injection or microneedle administration of virus-like-particle influenza vaccine. Advanced Healthcare Materials (small NANO MICRO), 2013 (04/2013; DOI:10.1002/adhm.201300006). Hyo-Jick Choi, Brian Bondy, Dae-Goon Yoo, Richard W. Compans, Sang-Moo Kang, Mark R. Prausnitz. Stability of influenza vaccine during coating onto microneedles. J Control Release 2013, 166(2):159-71. PMID: 23246470. Min-Chul Kim, Jae-Min Song, Eunju O, Young-Man Kwon, Youn-Jeong Lee, Richard W Compans, Sang-Moo Kang. Virus-like particles containing multiple M2 extracellular domains confer improved cross protection against various subtypes of influenza virus. Molecular Therapy 2013, 21(2): 485-492. PMID: 23247101. Prathap Nagaraja Shastri, Kim Minchul, Fu-Shi Quan, Martin J. D’souza, Sang Moo Kang. Immunogenicity and protection of oral influenza vaccines formulated into microparticles. Journal of Pharmaceutical Sciences 2012, 101(10): 3623-3635. PMID: 22711602. Bao-Zhong Wang, Harvinder Gill, Sang-Moo Kang, Li Wang, Ying-Chun Wang, Elena Vassilieva, and Richard Compans, Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a toll-like receptor ligand. Clinical and Vaccine Immunology 2012. 19(8): 1119-1125. Jae-Keun Park, Dong-Hun Lee, Ha-Na Youn, Myeong-Seob Kim, Yu-Na Lee, Seong-Su Yuk, Tae-Hyun Lim, Jun-Hyuk Jang, Sang-Moo Kang, Joong-Bok Lee, Seung-Yong Park, In-Soo Choi, Chang-Seon Song, Protective efficacy of crude virus-like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy. Influenza and Other Respiratory Viruses 2012, Jun 21. doi: 10.1111/j.1750-2659.2012.00396. Fu-Shi Quan, Min-Chul Kim, Byeong-Jae Lee, Jae-Min Song, Richard W. Compans, Sang-Moo Kang. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology 2012, 430(2): 127-135. PMID 22107852. Dae-Goon Yoo, Min-Chul Kim, Min-KyungPark, Jae-Min Song, Fu-Shi Quan, Kyoung-Mi Park, Young-Keol Cho, Sang-Moo Kang. Protective effect of Korean red ginseng extract on the infections by H1N1 and H3N2 influenza viruses in mice. J Medicinal Food 2012, 15(10):855-862. Dae-Goon Yoo, Min-Chul Kim, Min-KyungPark, Kyoung-Mi Park, Fu-Shi Quan, Jae-Min Song, Jae Joon Wee, Bao-Zhong Wang, Young-Keol Cho, Richard W. Compans, Sang-Moo Kang. Protective effect of ginseng polysaccharides on influenza viral infection. PLoS ONE 2012, 7(3): e33678. Yeu-Chun Kim, Jae-Min Song, Aleksandr S. Lipatov, Seong-O Choi, Jeong Woo Lee, Ruben O. Donis, Richard W. Compans, Sang-Moo Kang (Co-Corresponding), Mark R. Prausnitz. Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81(2):239-247. Jae-Min Song, Yeu-Chun Kim, Eunju O, Mark R. Prausnitz, Richard W. Compans, Sang-Moo Kang. DNA vaccination in the skin using microneedles improves protection against influenza. Molecular Therapy 2012, 20(7): 1472-1480. PMCID: 3392990. Fu-Shi Quan, Richard W. Compans, Sang-Moo Kang.Oral vaccination with inactivated influenza vaccines induces cross-protection. Vaccine 2012, 30(2), 180-188. Hyo-Jick Choi, Dae-Goon Yoo, Brian Bondy, Fu-Shi Quan, Richard W. Compans, Sang-Moo Kang, Mark R. Prausnitz. Stability of Influenza Vaccine Coated Onto Microneedles. Biomaterials 2012. 33(14): 3756-3769 Sang-Moo Kang, Jae-Min Song, Richard W. Compans, Novel vaccines against influenza viruses. Virus Research 2011,162(1-2): 31-8. Sang-Moo Kang, Min-Chul Kim, Richard W. Compans. Virus-like particles as universal influenza vaccines. Expert Review of Vaccines 2012, 11(8): 995-1007.